Oxytocin antagonist disrupts hypotension-evoked renin secretion and other responses in conscious rats

W Huang1, M Sjöquist, O Skott

  • 1Department of Neuroscience, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA.

Insights

Arterial hypotension increases oxytocin (OT) levels, which may help maintain cardiovascular homeostasis. Blocking OT receptors blunts the rise in renin activity and other responses to hypotension in rats.

Area of Science:

  • Cardiovascular Physiology
  • Endocrinology
  • Renal Physiology

Background:

  • Arterial hypotension is known to increase plasma oxytocin (OT) levels in rats.
  • Intravenous OT infusion can elevate plasma renin activity (PRA).

Purpose of the Study:

  • To investigate if blocking oxytocin receptors attenuates the increase in plasma renin activity during arterial hypotension in rats.

Main Methods:

  • Conscious male rats were subjected to hypotension using hydralazine or diazoxide.
  • An oxytocin receptor antagonist was administered intravenously.
  • Plasma renin activity, heart rate, and vasopressin levels were measured.

Main Results:

  • Hypotension induced by hydralazine or diazoxide significantly increased PRA.
  • The oxytocin receptor antagonist blunted the increase in PRA without affecting the induced hypotension.
  • The antagonist also reduced hypotension-evoked increases in heart rate and plasma vasopressin.

Conclusions:

  • Hypotension-evoked oxytocin secretion may contribute to cardiovascular homeostasis.
  • Oxytocin might enhance baroreceptor signals, stimulating renin, vasopressin, and heart rate responses during hypotension.

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hormonal Regulation of Blood Pressure01:17

Hormonal Regulation of Blood Pressure

Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...